A memorandum of understanding between the SEC and FDA formalizes information-sharing that increases dual oversight of corporate communications, according to BioXconomy (ID: 1c636c59b0329e52). The update targets enhanced access to FDA expertise during securities review and more systematic monitoring of how companies describe regulatory status and commercial outlook. For biotech and pharma leadership, the practical takeaway is stricter scrutiny of narrative disclosure sections and press releases tied to trials and approvals.